Related Experiment Video
Updated: Oct 28, 2025
09:16
High-sensitivity Detection of Micrometastases Generated by GFP Lentivirus-transduced Organoids Cultured from a Patient-derived Colon Tumor
Published on: June 14, 2018
10.3K
A Platform for Validating Colorectal Cancer Driver Genes Using Mouse Organoids.
1Laboratory of Molecular Genetics, National Cancer Center Research Institute, Tokyo, Japan.
Frontiers in Genetics
|July 15, 2021
Summary
Researchers need better ways to test cancer genes. This review highlights using mouse organoids and CRISPR-Cas9 to validate colorectal cancer (CRC) driver genes, improving cancer gene discovery.
Area of Science:
- Cancer Biology
- Genetics
- Organoid Technology
Background:
- Cancer genome sequencing has identified numerous mutated genes in tumors.
- Functional validation of these cancer genes is crucial but challenging.
- Mouse organoids accurately mimic in vivo tumor physiology, offering a powerful model system.
Purpose of the Study:
- To review the application of mouse organoids in colorectal cancer (CRC) research.
- To detail a platform for functionally validating CRC driver genes using CRISPR-Cas9 in mouse intestinal tumor organoids.
- To emphasize the utility of mouse organoids for cancer gene discovery and validation.
Main Methods:
- Utilized CRISPR-Cas9 gene editing technology.
- Employed mouse intestinal tumor organoids as a model system.
- Developed a platform for high-throughput functional gene validation.
Main Results:
- Demonstrated the feasibility of using CRISPR-Cas9 in mouse organoids for gene manipulation.
- Established a system for assessing the functional impact of specific gene mutations in CRC.
- Provided a framework for systematically validating potential CRC driver genes.
Conclusions:
- Mouse organoids are a valuable tool for studying colorectal cancer.
- The described platform enables efficient functional validation of CRC driver genes.
- This approach accelerates the identification of genes critical for colorectal cancer development and progression.
